Business
TETRA BIO-PHARMA - PRESS RELEASE CORRECTION
TETRA BIO-PHARMA - PRESS RELEASE CORRECTION.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTETRA BIO-PHARMA - PRESS RELEASE CORRECTION\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nTETRA BIO-PHARMA - PRESS RELEASE CORRECTION\nCanada NewsWire\nOTTAWA, Jan. 22, 2020\n\n\n\n/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES/\n OTTAWA, Jan. 22, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc.(TSXV:TBP) (\"Tetra\" or \"TBP\") announces a correction to its press release entitled \"TETRA BIO-PHARMA ANNOUNCES $10.0 MILLION BOUGHT DEAL OFFERING\" issued today (the \"Initial Press Release\").\nThe Initial Press Release incorrectly stated that the Offering, as defined therein, will be completed by way of a short form prospectus to be filed in all of the provinces and territories of Canada other than Quebec. However the Offering will be conducted in all the provinces of Canada, including Quebec, but excluding the territories of Canada. This correction does not change any other information reported in the Initial Press Release. \nAbout Tetra Bio-PharmaTetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. \nFor more information visit: www.tetrabiopharma.com\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nForward-looking statementsSome...